Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

May 4, 2021

Pfizer acquires San Diego biotech, adds to anti-infectives pipeline 


Pharma giant Pfizer has acquired a California biotech that has developed a treatment for potentially deadly fungal infections in people with compromised immune systems. 

Pfizer, which has a large Connecticut presence, said that the deal to acquire San Diego-based Amplyx Pharmaceuticals will allow it to expand its anti-infectives pipeline. 

Financial terms were not disclosed.

Amplyx’s lead drug compound fosmanogepix is in Phase 2 clinical trials. The drug aims to treat fungal strains that are resistant to other drugs. The deal also gives Pfizer the company’s early-stage pipeline of antiviral and antifungal therapies.

There has been no new therapeutic class of antifungal therapies approved by the U.S. Food and Drug Administration in nearly 20 years, according to Pfizer.

“We’ve already invested in assets that, if approved, could help address drug-resistant bacterial infections and critical viral infections,” Angela Lukin, global president, Pfizer Hospital, said in a statement. “We look forward to progressing the development of a novel antifungal as well.” 

Contact Natalie Missakian at

Sign up for Enews


Order a PDF